NDAORALFOR SUSPENSION, DELAYED RELEASE
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NOXAFIL POWDERMIX KIT (posaconazole) by Merck & Co. is 12. First approved in 2021.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOXAFIL POWDERMIX KIT (posaconazole) is an azole antifungal agent administered orally as a delayed-release suspension for prophylaxis and treatment of invasive fungal infections. It works by inhibiting fungal cell membrane ergosterol synthesis, preventing growth of Aspergillus and Candida species in severely immunocompromised patients. The product targets high-risk populations including neutropenic chemotherapy patients (AML/MDS) and hematopoietic stem cell transplant recipients with graft-versus-host disease.
Peak2.6 years to LOE
Product is at peak commercial stage post-2021 approval with Merck backing; moderate competitive pressure (30) suggests established team structure and ongoing optimization initiatives.
Mechanism of Action
12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Exposure Response Relationship: Prophylaxis of invasive Aspergillus and Candida Infections in Adults Who Are at High Risk of Developing These Infections Due to Being Severely Immunocompromised In…
Worked on NOXAFIL POWDERMIX KIT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.